StreetInsider.com News Articles

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference

Thu, 29 Oct 2026 13:05:00 -0500

Pulse Biosciences’ Management is scheduled to present on Thursday, November 12, at 11:20 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference

Thu, 29 Oct 2026 13:05:00 -0500

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

Thu, 22 Oct 2026 16:05:00 -0500

HAYWARD, Calif.--(BUSINESS WIRE)--

Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.

Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 9464498. A live and recorded webcast

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

Thu, 22 Oct 2026 16:05:00 -0500

HAYWARD, Calif.--(BUSINESS WIRE)--

Form 8-K PULSE BIOSCIENCES, INC. For: Oct 14

Wed, 14 Oct 2026 08:43:00 -0500

si-local-file:///var/storage/secattach/20261014/27184427.html

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Wed, 14 Oct 2026 07:00:00 -0500

Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to generate additional data on the use

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Wed, 14 Oct 2026 07:00:00 -0500

Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data

Pulse Biosciences (PLSE) PT Raised to $60 at Oppenheimer

Tue, 13 Oct 2026 06:02:12 -0500

Oppenheimer analyst Suraj Kalia raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $60.00 (from $35.00) while maintaining a Outperform rating.

The analyst comments "We recently accompanied PLSE management on a West Coast NDR. Competitor stumbles (Volt 2.0 events, concerns over JNJ’s EP franchise) highlight PLSE’s strategic value, as discussed during our meetings. As such, we are raising our price target on PLSE to $60 from $35. To be clear, much remains to be learned about the science of nsPFA. Hence, the pivotal trial readout (due CY27) will be crucial to complementing our understanding of this new PFA modality, the

Pulse Biosciences (PLSE) PT Raised to $60 at Oppenheimer

Tue, 13 Oct 2026 06:02:12 -0500

Oppenheimer analyst Suraj Kalia raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $60.00 (from $35.00) while maintaining a Outperform rating.

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 09 Oct 2026 16:05:00 -0500

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on October 8, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to two new employees to purchase, in aggregate,

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 09 Oct 2026 16:05:00 -0500

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on October 8, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to two new employees to purchase, in aggregate,

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Thu, 08 Oct 2026 07:00:00 -0500

Preclinical evaluation of nPulse™ prototype endocardial catheters highlighted in session presentation

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York.

A presentation at the Symposium will feature preclinical applications of two nPulse prototype endocardial catheters designed to demonstrate the potential for treatment of ventricular arrhythmias.

Presentation | Pulse Field Ablation of Ventricular Arrhythmias – Part II
Date:

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Thu, 08 Oct 2026 07:00:00 -0500

Preclinical evaluation of nPulse™ prototype endocardial catheters highlighted in session presentation

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York.
A presentation at the Symposium will feature preclinical applications of two nPulse prototype endocardial catheters designed to demonstrate the potential for treatment of ventricular arrhythmias.
Presentation | Pulse Field Ablation of Ventricular Arrhythmias – Part II
Date:

Form 8-K PULSE BIOSCIENCES, INC. For: Oct 07

Wed, 07 Oct 2026 09:06:00 -0500
si-local-file:///var/storage/secattach/20261007/27159001.html

Pulse Biosciences hits enrollment target in atrial fibrillation study

Wed, 07 Oct 2026 07:02:22 -0500

Pulse Biosciences, Inc. (Nasdaq: PLSE) announced it has reached its enrollment target of 164 evaluable patients across 15 clinical sites in its NANOPULSE-AF Study, a pivotal clinical investigation evaluating the nPulse Cardiac Catheter System for treating atrial fibrillation.
The study is a prospective, multicenter, non-randomized IDE pivotal investigation designed to assess the safety and effectiveness of the nPulse system in patients with drug-resistant, symptomatic, paroxysmal atrial fibrillation. The company said enrollment was completed three months ahead of its original nine-month timeline.
The first patients were treated at St. Bernards Medical Center in Jonesboro, Arkansas. Vivek Reddy, MD, Director of Cardiac Arrhythmia Services

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Wed, 07 Oct 2026 07:00:00 -0500

164 evaluable patients enrolled across 15 clinical sites

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites.
"The compelling first-in-human dataset from the nPulse Cardiac Catheter System created significant investigator interest within the EP community across the United States," said Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, New York, and National Principal Investigator of the NANOPULSE-AF Study. "With

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Wed, 07 Oct 2026 07:00:00 -0500

164 evaluable patients enrolled across 15 clinical sites

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites.
"The compelling first-in-human dataset from the nPulse Cardiac Catheter System created significant investigator interest within the EP community across the United States," said Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, New York, and National Principal Investigator of the NANOPULSE-AF Study. "With

Pulse Biosciences (PLSE) PT Raised to $58 at Canaccord

Tue, 06 Oct 2026 07:10:51 -0500
(Updated - October 6, 2026 7:10 AM EDT)
Canaccord analyst William Plovanic raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $58.00 (from $43.00) while maintaining a Buy rating.
The analyst commented: "We hosted Paul LaViolette, CEO, and Jon Skinner, CFO, for a virtual NDR for Pulse Biosciences last week. We initiated coverage on Pulse on June 4, 2026, and since then, PLSE is up 87.5% as investors have started to recognize the potential of the company’s differentiated nanosecond pulse field ablation (nsPFA) platform. During our meetings, we discussed the technology’s differentiation, its clinical evidence, potential use cases, and Pulse’s commercial

Pulse Biosciences (PLSE) PT Raised to $58 at Canaccord

Tue, 06 Oct 2026 07:10:51 -0500
(Updated - October 6, 2026 7:10 AM EDT)
Canaccord analyst William Plovanic raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $58.00 (from $43.00) while maintaining a Buy rating.
The analyst commented: "We hosted Paul LaViolette, CEO, and Jon Skinner, CFO, for a virtual NDR for Pulse Biosciences last week. We initiated coverage on Pulse on June 4, 2026, and since then, PLSE is up 87.5% as investors have started to recognize the potential of the company’s differentiated nanosecond pulse field ablation (nsPFA) platform. During our meetings, we discussed the technology’s differentiation, its clinical evidence, potential use cases, and Pulse’s commercial

BTIG Starts Pulse Biosciences (PLSE) at Buy

Wed, 23 Sep 2026 05:32:55 -0500
(Updated - September 23, 2026 5:32 AM EDT)
BTIG analyst Marie Thibault initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $70.00.
The analyst comments "Pulse Biosciences has developed a Nanosecond Pulsed Field Ablation (nsPFA) technology that operates meaningfully faster than commercially available microsecond PFA systems, enabling a circumferential, transmural cardiac ablation in a single five-second application. European first-in-human data in 141 patients (5-second cohort) showed 100% procedural success at six months, 96.2% at 12 months, and a Kaplan-Meier estimated 90% freedom from AF/AFL/AT at one year, better than published commercial PFA comparators. The NANOPULSE-AF

BTIG Starts Pulse Biosciences (PLSE) at Buy

Wed, 23 Sep 2026 05:32:55 -0500
(Updated - September 23, 2026 5:32 AM EDT)
BTIG analyst Marie Thibault initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $70.00.
The analyst comments "Pulse Biosciences has developed a Nanosecond Pulsed Field Ablation (nsPFA) technology that operates meaningfully faster than commercially available microsecond PFA systems, enabling a circumferential, transmural cardiac ablation in a single five-second application. European first-in-human data in 141 patients (5-second cohort) showed 100% procedural success at six months, 96.2% at 12 months, and a Kaplan-Meier estimated 90% freedom from AF/AFL/AT at one year, better than published commercial PFA comparators. The NANOPULSE-AF

Pulse Biosciences sets up $85M at-the-market stock offering

Tue, 15 Sep 2026 16:46:29 -0500

Pulse Biosciences, Inc. (NASDAQ: PLSE) entered into an equity distribution agreement with Mizuho Securities USA LLC on September 15, 2026, allowing the company to sell up to $85,000,000 in common stock through at-the-market offerings on the Nasdaq Capital Market.
Under the agreement, Mizuho will act as sales agent and receive a commission of up to 3.0% of the gross sales price of any shares sold. The company is not obligated to sell any shares and may suspend solicitations at any time.
The new agreement follows a prior equity distribution agreement the company entered into with Mizuho on August 6, 2026, which allowed

Pulse Biosciences sets up $85M at-the-market stock offering

Tue, 15 Sep 2026 16:46:29 -0500

Pulse Biosciences, Inc. (NASDAQ: PLSE) entered into an equity distribution agreement with Mizuho Securities USA LLC on September 15, 2026, allowing the company to sell up to $85,000,000 in common stock through at-the-market offerings on the Nasdaq Capital Market.
Under the agreement, Mizuho will act as sales agent and receive a commission of up to 3.0% of the gross sales price of any shares sold. The company is not obligated to sell any shares and may suspend solicitations at any time.
The new agreement follows a prior equity distribution agreement the company entered into with Mizuho on August 6, 2026, which allowed

Form 8-K PULSE BIOSCIENCES, INC. For: Sep 14

Tue, 15 Sep 2026 16:44:00 -0500
si-local-file:///var/storage/secattach/20260915/27065469.html

Form 424B5 PULSE BIOSCIENCES, INC.

Tue, 15 Sep 2026 16:44:00 -0500
si-local-file:///var/storage/secattach/20260915/27065462.html